Ponce Therapeutics, Inc. reunites the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a $161 million IPO. The team is retooling their original cell control technology with state-of-the-art advances towards their new goal of creating anti-aging products with a solid underlying scientific basis that actually work.
- The science of aging has continued to mature and can now provide a scientific basis for technologies to reverse the aging process in humans
- Proof of concept data in animal models demonstrates that removal of senescent cells from organs improves their function and imbues them with a more youthful profile
- Targeting p16-expressing cells for apoptotic elimination is one approach to removing senescent cells from the body
- Our lead product is a microneedle patch containing nanoparticles carrying our proprietary rapaCIDe cell elimination technology targeted to p16-expressing keratinocytes
- Our Phase I clinical trial program targets in situ carcinoma of the skin (Bowen’s disease) and seborrheic keratoses, which are nearly ubiquitous in the aging population, and which express high levels of p16
- We plan to extend our gene therapy clinical portfolio to include multiple other indications to reverse aging, such as androgenic alopecia
Reuniting the founders of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
He is also the founder and CEO of Ponce Therapeutics, Inc. (https://poncetherapeutics.com), which reunites the team that founded Bellicum Pharmaceuticals and is retooling their original cell control technology with state-of-the-art advances towards creating anti-aging products based on a scientific foundation, and DELiver Therapeutics, Inc. (https://delivertherapeutics.com), which is using novel, high throughput screening technologies to deliver therapeutics to address the most difficult problems in clinical medicine. Both have R&D facilities located at K2Bio in Houston (https://www.k2-biolabs.com/), a coworking research facility for biotech and pharma startups recently opened in Houston, where he is a co-founder, investor, and board member.
Slawin graduated magna cum laude with a Bachelor of Arts degree in Biochemistry from Columbia University, where he was inducted into Phi Beta Kappa. He earned his medical degree in 1986 from Columbia College of Physicians and Surgeons and was elected to the Alpha Omega Alpha honor society. He trained in General Surgery and then Urology at the Mount Sinai Hospital and at Squier Urologic Clinic at Columbia Presbyterian Hospital, both in NYC. Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer under the tutelage of renowned prostate cancer surgeon and thought leader, Dr. Peter Scardino. Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994 and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, established by the well-known Houston oil man and philanthropist of the same name. He is co-Inventor of the FDA-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America’s Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.
Before joining Bellicum, he served as the Vice Chairman of Pathology and Immunology at Baylor College of Medicine, where he was the Roger D Rossen Endowed Professor of Immunology. His lab focused on anti-cancer vaccination and animal modeling for prostate cancer, but his collaborative interests stretched into most areas of biology, such as Gene Regulation, Development, Cancer, Immunology and Aging. The animal models developed in his lab included the EZC-Prostate™ model for identifying and developing novel androgen axis inhibitors and the JOCK1 inducible prostate cancer model that demonstrated a critical inductive role of the Fibroblast Growth Factor Receptor 1(FGFR1) Axis in prostate cancer development.
He has published extensively in top scientific and medical journals, including Science, Nature, Nature Medicine, Molecular Cell, and NEJM and is also an inventor on at least 10 patent families, reflecting many areas of regulated cellular therapy. Dr. Spencer earned his BS in Chemistry (magna cum laude) at the University of California in San Diego and his Ph.D. in Biology from the Massachusetts Institute of Technology. He completed his postdoctoral degree at the Howard Hughes Medical Institute at Stanford University.
Through an agreement with Ponce Therapeutics, Inc., he currently also provides limited consulting CSO services to NanoCell Technologies, Inc.